Positive results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.
Genentech, a member of the Roche Group, announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor…